ParaZero Appoints New VP of Global Sales
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Source: Newsfilter
- Executive Appointment: ParaZero Technologies has appointed Bat-Sheva Noy as the new Vice President of Global Sales, and with over 20 years of commercial and leadership experience, her addition is expected to drive the company's global expansion in the drone safety and aerospace sector.
- Extensive Industry Background: Noy's previous role as Business Unit Lead for Rare Diseases at Pfizer involved strategy development and overall business performance, which will provide crucial support for ParaZero's market access and team development efforts.
- Educational and Military Experience: Noy holds an LL.B. in Law and a B.Sc. in Chemistry and Biology, and her service as an optical systems instructor in the Israel Defense Forces adds a solid foundation to her leadership capabilities and technical understanding.
- Company Vision: ParaZero aims to redefine the boundaries of aerial operations with intelligent, mission-ready systems, and Noy's appointment is expected to enhance the company's competitiveness in the rapidly evolving drone market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.960
Low
24.00
Averages
28.56
High
35.00
Current: 26.960
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IP Group PLC Reports 13% NAV Growth and Share Buyback Program
- NAV Growth: IP Group PLC (IPZYF) reported a 13% increase in NAV per share to 110p, driven by significant advancements in obesity drug compounds developed by Pfizer, which lays a solid foundation for future investments.
- Cash Flow and Buybacks: The company generated £68 million in cash exits, facilitating high-conviction investment opportunities and a buyback program that retired nearly 10% of shares, thereby enhancing shareholder confidence and improving capital structure.
- Portfolio Performance: Portfolio companies raised over £900 million in third-party capital, indicating strong external validation despite market challenges, attracting high-caliber global investors.
- Market Risks and Challenges: Despite positive financial performance, the company faces uncertainty regarding the clinical and regulatory progress of Pfizer's obesity drug, with only a 47% chance of success, while the capital intensity and high interest rates pose challenges for early-stage hydrogen businesses.
See More
PFIZER: LB6V VACCINE CANDIDATE SHOWS GOOD TOLERABILITY WITH NO SAFETY ISSUES FOUND DURING ANALYSIS
- Vaccine Candidate Tolerance: The Pfizer vaccine candidate was well tolerated by participants in clinical trials.
- Safety Concerns: No safety concerns were identified during the analysis of the vaccine candidate.
See More
PFIZER: INTENDS TO SUBMIT LB6V VACCINE CANDIDATE TO REGULATORS
- Pfizer's Vaccine Submission: Pfizer is preparing to submit applications for regulatory approval of its LB6V vaccine candidate.
- Regulatory Authorities Involvement: The submission will be directed to relevant regulatory authorities for evaluation and potential authorization.
See More
PFIZER: LB6V VACCINE CANDIDATE DEMONSTRATES OVER 70% EFFICACY IN LYME DISEASE PREVENTION FOR INDIVIDUALS AGED FIVE AND OLDER
- Vaccine Efficacy: Pfizer's vaccine candidate demonstrated over 70% efficacy in preventing Lyme disease.
- Target Population: The study focused on individuals aged five years and older.
See More
Trump Administration Delays Nomination for CDC Director
- Nomination Delay: The Trump administration has failed to nominate a new CDC director by the Wednesday deadline, resulting in NIH chief Jay Bhattacharya continuing to lead the CDC, although he will lose the acting director title.
- Candidate Vetting: According to The Washington Post, the White House is taking its time to vet about six candidates, indicating a cautious approach amid growing political and operational pressures in selecting CDC leadership.
- Candidate List: Cardiologist Joseph Marine from Johns Hopkins Medicine and former Kentucky Governor Ernie Fletcher are among the contenders, reflecting the diversity in potential candidates being considered by the administration.
- Historical Context: During Trump's second term, the CDC has primarily been led by acting directors, with former director Susan Monarez being fired for refusing to follow orders from HHS Secretary Robert F. Kennedy Jr., highlighting instability within CDC leadership.
See More
PFIZER: GUGGENHEIM INCREASES TARGET PRICE TO $36, UP FROM $35
- Price Increase Announcement: Pfizer has raised the target price for its stock from $35 to $36.
- Market Impact: This adjustment reflects the company's confidence in its financial performance and future prospects.
See More
IP Group PLC Reports 13% NAV Growth and Share Buyback Program
- NAV Growth: IP Group PLC (IPZYF) reported a 13% increase in NAV per share to 110p, driven by significant advancements in obesity drug compounds developed by Pfizer, which lays a solid foundation for future investments.
- Cash Flow and Buybacks: The company generated £68 million in cash exits, facilitating high-conviction investment opportunities and a buyback program that retired nearly 10% of shares, thereby enhancing shareholder confidence and improving capital structure.
- Portfolio Performance: Portfolio companies raised over £900 million in third-party capital, indicating strong external validation despite market challenges, attracting high-caliber global investors.
- Market Risks and Challenges: Despite positive financial performance, the company faces uncertainty regarding the clinical and regulatory progress of Pfizer's obesity drug, with only a 47% chance of success, while the capital intensity and high interest rates pose challenges for early-stage hydrogen businesses.
See More
PFIZER: LB6V VACCINE CANDIDATE SHOWS GOOD TOLERABILITY WITH NO SAFETY ISSUES FOUND DURING ANALYSIS
- Vaccine Candidate Tolerance: The Pfizer vaccine candidate was well tolerated by participants in clinical trials.
- Safety Concerns: No safety concerns were identified during the analysis of the vaccine candidate.
See More
PFIZER: INTENDS TO SUBMIT LB6V VACCINE CANDIDATE TO REGULATORS
- Pfizer's Vaccine Submission: Pfizer is preparing to submit applications for regulatory approval of its LB6V vaccine candidate.
- Regulatory Authorities Involvement: The submission will be directed to relevant regulatory authorities for evaluation and potential authorization.
See More
PFIZER: LB6V VACCINE CANDIDATE DEMONSTRATES OVER 70% EFFICACY IN LYME DISEASE PREVENTION FOR INDIVIDUALS AGED FIVE AND OLDER
- Vaccine Efficacy: Pfizer's vaccine candidate demonstrated over 70% efficacy in preventing Lyme disease.
- Target Population: The study focused on individuals aged five years and older.
See More
Trump Administration Delays Nomination for CDC Director
- Nomination Delay: The Trump administration has failed to nominate a new CDC director by the Wednesday deadline, resulting in NIH chief Jay Bhattacharya continuing to lead the CDC, although he will lose the acting director title.
- Candidate Vetting: According to The Washington Post, the White House is taking its time to vet about six candidates, indicating a cautious approach amid growing political and operational pressures in selecting CDC leadership.
- Candidate List: Cardiologist Joseph Marine from Johns Hopkins Medicine and former Kentucky Governor Ernie Fletcher are among the contenders, reflecting the diversity in potential candidates being considered by the administration.
- Historical Context: During Trump's second term, the CDC has primarily been led by acting directors, with former director Susan Monarez being fired for refusing to follow orders from HHS Secretary Robert F. Kennedy Jr., highlighting instability within CDC leadership.
See More
PFIZER: GUGGENHEIM INCREASES TARGET PRICE TO $36, UP FROM $35
- Price Increase Announcement: Pfizer has raised the target price for its stock from $35 to $36.
- Market Impact: This adjustment reflects the company's confidence in its financial performance and future prospects.
See More
